ATE360002T1 - Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen - Google Patents

Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Info

Publication number
ATE360002T1
ATE360002T1 AT03716415T AT03716415T ATE360002T1 AT E360002 T1 ATE360002 T1 AT E360002T1 AT 03716415 T AT03716415 T AT 03716415T AT 03716415 T AT03716415 T AT 03716415T AT E360002 T1 ATE360002 T1 AT E360002T1
Authority
AT
Austria
Prior art keywords
producing
propanediaminesulfamid
pyridyl
acid
biologically active
Prior art date
Application number
AT03716415T
Other languages
English (en)
Inventor
Anita Wai-Yin Chan
Gregg Brian Feigelson
Joseph Zeldis
Ivo Jirkovsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE360002T1 publication Critical patent/ATE360002T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03716415T 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen ATE360002T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12

Publications (1)

Publication Number Publication Date
ATE360002T1 true ATE360002T1 (de) 2007-05-15

Family

ID=28041771

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03716415T ATE360002T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
AT07007755T ATE449073T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07007755T ATE449073T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Country Status (26)

Country Link
US (1) US6784294B2 (de)
EP (2) EP1483243B1 (de)
JP (1) JP4397693B2 (de)
KR (1) KR20040091720A (de)
CN (1) CN100341854C (de)
AR (1) AR038932A1 (de)
AT (2) ATE360002T1 (de)
AU (1) AU2003220122A1 (de)
BR (1) BR0308315A (de)
CA (1) CA2477886A1 (de)
CY (1) CY1106677T1 (de)
DE (2) DE60330199D1 (de)
DK (1) DK1483243T3 (de)
EC (1) ECSP045291A (de)
ES (2) ES2334836T3 (de)
IL (1) IL163829A0 (de)
MX (1) MXPA04008731A (de)
NO (1) NO20044049L (de)
NZ (1) NZ535170A (de)
PT (1) PT1483243E (de)
RU (1) RU2314294C2 (de)
SI (1) SI1483243T1 (de)
TW (1) TWI288642B (de)
UA (1) UA80272C2 (de)
WO (1) WO2003078396A1 (de)
ZA (1) ZA200408213B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
JP4397693B2 (ja) 2002-03-12 2010-01-13 ワイス N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用
BR0308347A (pt) * 2002-03-12 2005-01-25 Wyeth Corp Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
EP2602248A1 (de) 2011-12-05 2013-06-12 University Of Leicester Neue Pyrrol Verbindungen
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189612B1 (de) 1984-12-21 1992-11-04 Duphar International Research B.V Arzneimittel mit psychotroper Wirkung
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
WO1994024115A1 (fr) 1993-04-16 1994-10-27 Santen Pharmaceutical Co., Ltd. Nouveau derive de piperazine
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
JPH10504275A (ja) * 1994-06-03 1998-04-28 ジョン・ワイス・アンド・ブラザー・リミテッド ピペラジン誘導体を製造するための新規な方法および中間体
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αvβ3拮抗薬
ES2329122T3 (es) * 2002-03-12 2009-11-23 Wyeth Procedimiento para sintetizar n-aril piperazinas quirales.
JP4397693B2 (ja) 2002-03-12 2010-01-13 ワイス N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用

Also Published As

Publication number Publication date
WO2003078396A1 (en) 2003-09-25
ATE449073T1 (de) 2009-12-15
ZA200408213B (en) 2007-03-28
SI1483243T1 (sl) 2007-08-31
US6784294B2 (en) 2004-08-31
AU2003220122A1 (en) 2003-09-29
ES2283762T3 (es) 2007-11-01
CA2477886A1 (en) 2003-09-25
NO20044049L (no) 2004-09-24
JP4397693B2 (ja) 2010-01-13
US20030204087A1 (en) 2003-10-30
PT1483243E (pt) 2007-06-27
RU2004130314A (ru) 2005-04-10
EP1801103A1 (de) 2007-06-27
AR038932A1 (es) 2005-02-02
WO2003078396A8 (en) 2004-01-29
TWI288642B (en) 2007-10-21
ECSP045291A (es) 2004-10-26
CY1106677T1 (el) 2012-05-23
DE60313301D1 (de) 2007-05-31
IL163829A0 (en) 2005-12-18
CN100341854C (zh) 2007-10-10
ES2334836T3 (es) 2010-03-16
DE60313301T2 (de) 2007-12-27
JP2005526088A (ja) 2005-09-02
TW200303751A (en) 2003-09-16
BR0308315A (pt) 2004-12-28
MXPA04008731A (es) 2004-12-06
EP1801103B1 (de) 2009-11-18
KR20040091720A (ko) 2004-10-28
EP1483243B1 (de) 2007-04-18
UA80272C2 (en) 2007-09-10
EP1483243A1 (de) 2004-12-08
RU2314294C2 (ru) 2008-01-10
HK1068618A1 (en) 2005-04-29
NZ535170A (en) 2006-03-31
DK1483243T3 (da) 2007-08-06
CN1642916A (zh) 2005-07-20
DE60330199D1 (de) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE476412T1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE473227T1 (de) 5,6-dialkyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
DE50207943D1 (de) Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
ATE342071T1 (de) Implantat mit poröser proteinmatrix und verfahren zu seiner herstellung
DE60313602D1 (de) N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
DE60205555D1 (de) Fluorinierte cycloolefinpolymere und verfahren zu deren herstellung, sowie deren verwendung
DE60225561D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung
DE10393704D2 (de) Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE360002T1 (de) Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
DE69812365D1 (de) Enthaarungsmitteln, verfahren zur herstellung sowie ihre verwendung
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
ATE388265T1 (de) Wildlederartiges kunstleder und verfahren zu dessen herstellung
DE60103395D1 (de) 1,4-diazabicyclo[3.2.2]nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
DE60236790D1 (de) Piezoelektrischer oszillator und verfahren zu seiner herstellung
DE69901689D1 (de) Salze der ketosäuren und amine sowie ihre verwendung zur herstellung von medikamenten
DE50206824D1 (de) Befestigungselement und verfahren zu seiner herstellung sowie verwendung
ATE329947T1 (de) Polyolefinzusammensetzung, verfahren zur herstellung und die verwendung davon
AT502793A5 (de) Grobkeramischer formkörper, verfahren zu dessen herstellung und verwendung
DE60223714D1 (de) Verfahren zur herstellung von monofilamenten aus polypropylen, monofilamente aus polypropylen sowie deren verwendung
ATE404532T1 (de) Acyl-3-carboxyphenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
DE50012584D1 (de) Keramikhaltiges dispergat, verfahren zu dessen herstellung und verwendung des dispergates in dickschichtpasten
ATE302765T1 (de) 2-arylimino-2,3-dihydrothiazol derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE60135156D1 (de) Katalysatorzusammensetzung und verfahren unter verwendung dieser zusammensetzung
ATE415090T1 (de) Ammonium glyphosate und verfahren zur dessen herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483243

Country of ref document: EP

REN Ceased due to non-payment of the annual fee